MX338610B - Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa. - Google Patents

Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.

Info

Publication number
MX338610B
MX338610B MX2013015002A MX2013015002A MX338610B MX 338610 B MX338610 B MX 338610B MX 2013015002 A MX2013015002 A MX 2013015002A MX 2013015002 A MX2013015002 A MX 2013015002A MX 338610 B MX338610 B MX 338610B
Authority
MX
Mexico
Prior art keywords
sulbactam
beta
pharmaceutical compositions
lactamase inhibitor
acceptable salt
Prior art date
Application number
MX2013015002A
Other languages
English (en)
Other versions
MX2013015002A (es
Inventor
Manesh Vithalbhai Patel
Sachin Bhagwat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013015002A publication Critical patent/MX2013015002A/es
Publication of MX338610B publication Critical patent/MX338610B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones y métodos para tratar o prevenir infecciones bacterianas. Las composiciones farmacéuticas comprenden típicamente una cantidad farmacéuticamente efectiva de: (a) sulbactam o su sal farmacéuticamente aceptable, y (b) por lo menos un inhibidor de beta-lactamasa o una sal de ella, aceptable para uso farmacéutico, a condición de que el inhibidor de beta lactamasa no sea sulbactam.
MX2013015002A 2011-07-26 2011-10-04 Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa. MX338610B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2125MU2011 2011-07-26
PCT/IB2011/054349 WO2013014496A1 (en) 2011-07-26 2011-10-04 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor

Publications (2)

Publication Number Publication Date
MX2013015002A MX2013015002A (es) 2014-10-22
MX338610B true MX338610B (es) 2016-04-25

Family

ID=44925586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015002A MX338610B (es) 2011-07-26 2011-10-04 Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.

Country Status (13)

Country Link
US (1) US9744160B2 (es)
EP (1) EP2736508A1 (es)
JP (1) JP5808860B2 (es)
KR (1) KR101737167B1 (es)
CN (1) CN103687598B (es)
AU (1) AU2011373911B2 (es)
BR (1) BR112013032711A2 (es)
CA (1) CA2842777C (es)
MX (1) MX338610B (es)
NZ (1) NZ616806A (es)
RU (1) RU2560846C1 (es)
WO (1) WO2013014496A1 (es)
ZA (1) ZA201307956B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2569059C2 (ru) * 2011-07-26 2015-11-20 Вокхардт Лимитед Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015059643A1 (en) * 2013-10-22 2015-04-30 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
IN2013MU03421A (es) * 2013-10-30 2015-07-17 Wockhardt Ltd
KR20160126004A (ko) * 2014-03-14 2016-11-01 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조성물
BR112016022439A2 (pt) * 2014-03-29 2017-08-15 Wockhardt Ltd Composições farmacêuticas que compreendem cefepima ou sulbactama
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
RU2589929C1 (ru) * 2015-08-12 2016-07-10 Олег Иванович Квасенков Способ производства хлебного кваса
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
MA48743A (fr) 2017-05-08 2020-04-08 Entasis Therapeutics Inc Composés et méthodes de traitement d'infections bactériennes
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CA3110111A1 (en) 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109864970A (zh) * 2019-04-22 2019-06-11 苏州东瑞制药有限公司 一种舒巴坦钠组合物无菌粉及其制备方法
CN113559099A (zh) * 2021-08-27 2021-10-29 丹诺医药(苏州）有限公司 包含舒巴坦和阿维巴坦的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1206261T3 (da) * 1999-08-16 2006-07-03 Revaax Pharmaceuticals Llc Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
US20090275552A1 (en) * 2006-04-28 2009-11-05 Mahesh Vithalbhai Patel Therapy for Treating Resistant Bacterial Infections
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN102106857B (zh) * 2009-12-29 2012-07-18 齐鲁动物保健品有限公司 注射用复方头孢噻呋钠冻干粉针剂

Also Published As

Publication number Publication date
NZ616806A (en) 2015-03-27
EP2736508A1 (en) 2014-06-04
ZA201307956B (en) 2015-01-28
MX2013015002A (es) 2014-10-22
CN103687598B (zh) 2016-03-16
US9744160B2 (en) 2017-08-29
CA2842777A1 (en) 2013-01-31
CN103687598A (zh) 2014-03-26
JP5808860B2 (ja) 2015-11-10
RU2560846C1 (ru) 2015-08-20
AU2011373911B2 (en) 2016-09-22
KR20140053900A (ko) 2014-05-08
AU2011373911A1 (en) 2013-11-07
JP2014521631A (ja) 2014-08-28
CA2842777C (en) 2015-12-29
US20140094447A1 (en) 2014-04-03
KR101737167B1 (ko) 2017-05-17
BR112013032711A2 (pt) 2017-01-17
WO2013014496A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2014DN10670A (es)
NZ730809A (en) Methods for treating filoviridae virus infections
WO2013122888A3 (en) Methods of treating bacterial infections
MY196240A (en) Combination Therapy for Treatment Of Resistant Bacterial Infections
MX338327B (es) Inhibidores de cdk.
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
TN2012000458A1 (en) Uses of dgat1 inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
AU2012225365A8 (en) Peptide deformylase inhibitors
MX2016005869A (es) Inhibidor de beta-lactamasa cristalina.
HK1236202A1 (en) Beta-lactamase inhibitors
NZ780408A (en) Human plasma kallikrein inhibitors
UA88315U (en) Antibacterial composition
JOP20120346B1 (ar) مركبات لعلاج ومنع الإلتصاق، وتركيبات صيدلية متعلقة بالمركب وطرق لمنع وعلاج الإلتصاقات
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
MY182136A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration